US20110200614A1

US20110200614A1 - Anthrax specific antibodies

Info

Publication number: US20110200614A1
Application number: US12/619,489
Authority: US
Inventors: Beverly Lynn Mangold; Jennifer Lynn Aldrich; Thomas W. O'Brien
Original assignee: Individual
Current assignee: Individual
Priority date: 2000-04-28
Filing date: 2009-11-16
Publication date: 2011-08-18
Also published as: US7618783B2; EP1280828B1; CA2420287A1; US20020082386A1; WO2001083561A3; EP1280828A2; DE60123036T2; AU2001259204A1; WO2001083561A2; DE60123036D1; ATE339449T1

Abstract

The present invention is directed to diagnostic tools and therapies using antibodies to Bacillus anthracis. Specifically, the present invention is directed to a B. anthracis-specific monoclonal antibody that binds to the EA1 antigen (corresponding to the eag gene) of the S-layer (surface layer) of spores. This monoclonal antibody may be used in a variety of applications, including to specifically detect and diagnose B. anthracis. Preferably, antibodies are monoclonal and bind to a surface protein, such as EA1 protein, on the spores of B. anthracis, and not to spores of either B. cereus or B. thuringiensis. Antibodies can be incorporated into detection kits using, for example, colloidal particle based lateral flow detection system. Such detection kits can distinguish anthrax spores from non-pathogenic varieties of spores. In addition, the invention is directed to B. anthracis EA1 antigen and pharmaceuticals such as vaccines that can be used as therapeutics and to develop improved antibodies and detection methods.

Description

REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. Provisional patent application No. 60/200,505, entitled “Anthrax Specific Antibodies,” filed Apr. 28, 2000.

BACKGROUND OF THE INVENTION

1. Field of the Invention
This invention relates to antibodies to anthrax, and, in particular, to Bacillus species-specific antibodies that bind to the EA1 antigen of the S-layer, and to methods for making and using these antibodies. The invention further relates to kits that contain Bacillus species-specific antibodies for the rapid detection and identification of individual Bacillus species. The invention further relates to isolated EA1 antigen and compositions that contain the EA1 antigen for use as pharmaceuticals.
2. Description of the Background
Anthrax is a world wide disease of sheep, cattle, horses and other mammals caused by the spore-forming, saprophytic bacterium, Bacillus anthracis. Soil, the most common location of anthrax spores, typically becomes contaminated from the carcasses of infected animals that have died. Spores from the decaying carcasses are deposited in the soil, in the water and on vegetation. Like most types of spores, anthrax spores are very resistant to environmental changes such as extremes of heat and cold, and severe desiccation. Consequently, undisturbed spores can remain viable for decades.
Infection usually begins by entry of spores through injured skin or mucous membranes. Spores germinate at the site of entry and proliferate. Although not generally considered a respiratory pathogen, anthrax spores can initiate infection through the lungs. For example, Woolsorter's Disease, a rare from of anthrax, is caused by the inhalation of large quantities of anthrax spores from the dust of wool, hair or hides. Deep, concentrated inhalation results in the germination of spores in lung tissue and tracheobronchial lymph nodes. Unchecked, this disease is almost always fatal with symptoms which include the production of hemorrhagic mediastinitis, pneumonia, meningitis and sepsis. In anthrax sepsis, the number of organisms in the blood can exceed ten million per milliliter prior to death.
Most animals are susceptible to anthrax, but resistance is not uncommon (e.g. rat). In resistant animals, organisms proliferate for a few hours while also generating a massive accumulation of leukocytes. In these animals, dying organisms remain confined to capsules which gradually disintegrate and disappear. In susceptible animals, organisms germinate and rapidly proliferate at the site of entry. The most common portal of entry in animals is the mouth and the gastrointestinal tract. Spores within contaminated soil find easy access when ingested with spiny or other irritating vegetation. In humans, scratches of the skin and other injuries are the most likely routes of infection. Germination and growth of the vegetative organisms results in formation of a gelatinous edema and congestion with a generation of large amounts of proteinaceous fluid containing leukocytes. Bacilli spread via lymphatics to the bloodstream and multiply freely in blood and tissues shortly before death of the animal. In the plasma of animals dying from anthrax, a toxic factor has been identified. This factor kills mice upon inoculation and is specifically neutralized by anthrax antiserum.
Two factors are believed to be responsible for the toxic effect of anthrax infection; an edematogenic factor (EF) and a lethal factor (LF). These in combination with a membrane binding factor or protective antigen (PA), may have the capacity to confer active protection against disease (PNAS 79:3162-66, 1982). The genes which encode these protein factors (pag for PA, cya for EF, and lef for LF) have been cloned and sequenced (see Gene 69:287-300, 1988; Gene 71:293-98, 1988; and Gene 81:45-54, 1989). A recombinant strain of B. anthracis has been produced which is unable to produce LE or EF (U.S. Pat. No. 5,840,312). This strain has been used to create immunogenic compositions against anthrax infection.
Active immunity to anthrax can be induced in susceptible animals by vaccination with live attenuated bacilli, with spore suspensions, or with protective antigens from culture filtrates. Immunity is often incomplete and not long lasting so that the preferred treatment of choice is a course of antibiotics. If started early, antibiotic therapy has a high success rate.
As an acute, febrile disease of virtually all warm-blooded animals, including man, anthrax has been used in biological weapons. Terrorists have included dry spores in letters to target specific individuals for harassment. Biological weapons of mass destruction have been developed that contain large quantities of anthrax spores for release over enemy territory. Once released, spores contaminate a wide geographical area, infecting nearly all susceptible mammals. Due to the spore's resistance to heat and dry conditions, contaminated land can remain a danger for years. In view of the serious threat posed by the disease, effective diagnostic tools are needed to assist in prevention and control of natural and man-made outbreaks.

DESCRIPTION OF THE DRAWINGS

FIG. 1 Amino Acid sequence of mature EA1 protein (SEQ ID NO. 1).

FIG. 2 Competitive inhibition assays of anthrax-specific antibodies.

SUMMARY OF THE INVENTION

The present invention overcomes the problems and disadvantages associated with current strategies and designs and provides new compositions and methods for the detection and identification of anthrax.
One embodiment of the invention is directed to antibodies that are specifically reactive against spores of B. anthracis, and preferably not specifically reactive against B. cereus or B. thuringiensis. Antibodies may be of any isotype, such as IgA, IgD, IgE, IgG, IgM, or of any sub-type. Further, the invention also includes reactive fragments of these antibodies such as Fab or Fv fragments, or other antigenically active portions thereof. Antibodies may be directed to antigen on the surface of anthrax such as, for example, the EA1 antigen and, preferably, SEQ ID NO. 1, and fragments of this antigen or polypeptide. Anthrax-specific antibodies may be isolated and purified, polyclonal or monoclonal, or created by recombinant engineering techniques and include, for example, humanized antibodies.
Another embodiment of the invention is directed to a method of producing a species-specific monoclonal antibody to spores of one species of Bacillus such as, for example, B. anthracis. B. cereus or B. Thuringiensis. Preferably the method comprises immunizing a host with a preparation of Bacillus spores of on species, followed by boosting the host with spores of another species of the same genus, preferably an antigenically similar species. This boost, preferably at about seven days prior to fusion, stimulates clones that share specificity between the species of interest and the near neighbor so that, at the time of fusion, these clones will have diminished capacity to be fused. A second boost is administered to the host via, for example, an intravenous route (or intra peritoneal, subcutaneous, etc.), with the preparation of spores of interest from the target species. This second boost, preferably at about three days prior to fusion, stimulates clones that haven't already been stimulated by the antigenically similar boost such that the species-specific clones will be maximally susceptible to being fused. Antibody-producing cells are fused with immortalized cells and the anthrax specific hybridomas selected.
Another embodiment of the invention is directed to hybridomas that express Bacillus species-specific monoclonal antibodies such as anthrax-specific antibodies. These cell lines may be derived from nearly any mammal as well as other species such as, for example, cattle, chickens, goats, guinea pigs, horses, mice, pigs, primates, rabbits, rats and sheep.
Another embodiment of the invention is directed to diagnostic kits which incorporate Bacillus species-specific antibodies, and preferably anthrax-specific antibodies. Kits further contain a detection system such as, for example, a colloidal particle-based lateral flow system, a carbon-based lateral flow system, a fluorescent-based assay system, a chemiluminescent system, an up-converting phosphors system, a refractive index-based detection system, magnetic bead or latex bead systems, or a micro array system.
Another embodiment of the invention is directed to recombinant or isolated EA1 antigen from B. anthracis for use as a therapeutic. Recombinant or affinity purified EA1 antigen when, for example, combined with a pharmaceutically acceptable carrier, can be used as a therapy against the disease in a vaccine. Further, therapeutically effective doses of isolated or purified antibodies to the EA1 antigen, and active portions thereof, may also be effective in prophylaxis or treatment.
Other embodiments and advantages of the invention are set forth in part in the description which follows, and in part, will be obvious from this description, or may be learned from the practice of the invention.

DESCRIPTION OF THE INVENTION

As embodied and broadly described herein, the present invention comprises methods for the creation and use of antibodies that are specifically reactive against species of Bacillus such as, for example, B. anthracis, B. thuringiensis and B. Cereus. The invention further includes kits for the detection of individual Bacillus species such as B. anthracis and compositions that can be incorporated into vaccines and therapies to prevent or control disease.
Conventional methods for the detection of pathogenic infection by B. anthracis are slow and often subject to interpretation. These shortcoming can be directly attributed to an inability to distinguish pathogenic B. anthracis from closely-related, non-pathogenic species.
It has been discovered that identifiable epitopes exist that are unique to species of Bacillus such as, for example, B. anthracis. This surprising discovery was made by creating a species-specific antibody to anthrax, utilizing a procedure to maximize unique or distinguishing immunological features. One distinguishing feature of anthrax was found to be a surface protein, specifically the EA1 antigen, which is found in preparations of both spores and vegetative cells. By making the EA1 antigen of B. anthracis a preferred target for immunological detection, new diagnostic tools, therapies and treatments are available.
One embodiment of the invention is directed to species-specific antibodies to species of Bacillus such as, for example, antibodies that are specifically reactive against B. anthracis, B. thuringiensis or B. cereus. These antibodies may be monoclonal or polyclonal, recombinant or purified from natural sources, and be of any isotype such as IgA, IgD, IgE, IgG, or IgM, or any sub-type (e.g. IgG1, IgG2a, IgG2b). Purified antibodies may be obtained from infected animals and affinity purified, HPLC purified, or purified using other procedures known to those of ordinary skill in the art. Recombinant antibodies may be made from the genetic elements which encode anthrax-specific antibodies. These genetic elements can be expressed in a variety of systems, and large quantities of antibody, or active portions of antibodies, manufactured. Further, the invention includes reactive portions of any of these antibodies of the invention (e.g. Fab and Fv fragments), which may be used in isolation, in combination or in construction of recombinant antibodies such as, for example, humanized antibodies. Preferably, anthrax-specific antibodies are directed against the EM antigen, SEQ ID NO. 1, or antigenic parts of this antigen, such as a polypeptide having amino acids 181-833 of the EA1 protein.
Another embodiment of the invention is directed to a method of producing a species-specific monoclonal antibody to one species of Bacillus. This method preferably comprises first immunizing a host animal with a preparation of the species of interest such as, for example, B. anthracis, B. cereus or B. thuringiensis, which are all antigenically similar. Preparations may comprise spores, vegetative cells or combinations thereof. The host animal may be any animal suitable for the production of monoclonal antibodies such as, preferably, mice. Preferably about seven days prior to fusion, administering an intravenous boost using a preparation from another species of the same genus as the species used during the immunization. Preferably, this species are of an antigenically similar, but not identical, species. For example, when selecting for antibodies specific to B. cereus, either B. anthracis or B. thuringiensis may be used as the antigenically similar source. When selecting for antibodies specific to B. anthracis, either B. cereus or B. thuringiensis may be used as the antigenically similar source. This stimulates clones that share specificity between the species of interest and the near neighbor species. However, by the time of fusion about seven days later, these clones will have diminished capacity to be fused. Next, and preferably about three days prior to fusion, administering another boost via, for example, an intravenous route (intra peritoneal, subcutaneous, etc.), with a preparation of the species of interest. This stimulates clones that haven't already been stimulated by the antigenically similar boost, the specific clones. These species-specific clones should be maximally susceptible to being fused three days later. Thus, the number of cross-reacting clones should be greatly reduced or eliminated in the fusion products and a species-specific monoclonal antibody should be favored. Additional or fewer boosts may be performed and at various times to maximize generation of anthrax-specific hybridomas, as may be determined by one of ordinary skill in the art.
Antibody-producing cells are selected and fused with non-antibody producing cells such as, for example, immortalized cell lines. These fusion partners are typically transformed mouse cells such as myeloma cells of the mouse. After fusion, fused cells are segregated into individual cultures and propagated, and hybridoma lines which express anthrax-specific monoclonal antibodies are selected. Further, using these same methods and procedures, spore-specific and vegetative-specific epitopes can be identified and antibodies created. These cell lines can be maintain in culture or cryopreserved using techniques well known to those of ordinary skill in the art. This general method can be used to select for species-specific antigens (and antibodies) between any two antigenically similar species whether they be spores, vegetative cells, viruses, phage, fungi, animal or plant cells, or any other types of microorganism.
Another embodiment of the invention is directed to hybridomas that express Bacillus species-specific monoclonal antibodies of the invention. These cell lines may be derived from nearly any mammal as well as other species such as, for example, cattle, chickens, goats, guinea pigs, horses, mice, pigs, primates, rabbits, rats and sheep. Preferably, the Bacillus species is anthrax and the hybridoma expresses anthrax-specific antibodies to aid in the detection of anthrax.
Another embodiment of the invention is directed to a diagnostic kit for the detection of individual species of Bacillus, such as, for example, anthrax. Anthrax, as well as non-pathogenic species of Bacillus, can be detected from, for example, spores and vegetative cells on nearly any material. For example, spores on any surface can be collected using conventional procedures (e.g. swipes, vacuums, washings) and tested. Samples can also be taken from patients or the environment. Biological samples include, for example, liquids such as blood, plasma, urine, bile, cerebrospinal fluid, lymph fluid, amniotic fluid or peritoneal fluid. Tissues may also be tested and samples obtained from organs, skin, hair, fingernails or nearly any area of the body. Environmental samples include, for example, samples collected from rivers and streams, salt or fresh water bodies, soil or rock, or samples of biomass. Detection kits comprise anthrax-specific antibodies or antibody fragments and a suitable detection system. The antibody or antibody fragment may be a whole antibody such as an IgG or an antibody fragment such as Fab or Fv fragment, or a minimum antigen-binding fragment. Detection kits may comprise solid supports for Bacillus or anthrax-specific antibodies, antigen or label, as appropriate. Suitable labels include, for example, radioactive labels, electromagnetic labels, electric field labels, fluorescent labels, enzyme labels, chemiluminescent labels, colored labels, and, preferably, visually perceptible labels. Detection systems may involve labeling the antibodies with a detectable label or a labeled secondary antibody that recognizes and binds to antigen-antibody complexes formed between, for example, anthrax spores and anthrax-specific antibodies of the invention. Preferably, the detectable label is visually detectable such as an enzyme, fluorescent chemical, luminescent chemical or chromatic chemical, which would facilitate determination of test results for the user or practitioner. Preferably the detection system is a colloidal particle based lateral flow detection system. Other detection systems include carbon based lateral flow system, a fluorescent based assay system, a chemiluminescent system, an up converting phosphors system, a refractive indexed based detection system, a magnetic bead or latex bead system, and a micro array system.
Diagnostic kits may further comprise agents to increase stability, shelf-life, inhibit or prevent product contamination and increase detection speed. Useful stabilizing agents include water, saline, alcohol, detergents, glycols including polyethylene glycol, oils, starches, sugars and polysaccharides, salts, glycerol, stabilizers, emulsifiers and combinations thereof. Useful antibacterial agents include antibiotics, bacterial-static and bacterial-toxic chemicals. Agents to optimize speed of detection may increase reaction speed such as salts and buffers. Using these procedures and components, kits can be created for the detection of anthrax. In addition, kits mat also be created for the detection on non-pathogenic strains of Bacillus. Such kits are useful as training tools and as controls in the detection of anthrax.
Another embodiment of the invention is directed to an antigen comprising an EA1 antigen (corresponding to eag gene) of the S-layer (surface layer) of B. anthracis (FIG. 1). This antigen is found in both spore and vegetative cell preparations of anthrax and can be isolated and purified, for example, using affinity chromatography. The corresponding gene can also be cloned and sequenced. As a unique antigenic marker for pathogenic anthrax, this protein may be used as a therapeutic pharmaceutical or vaccine to prevent infection.
Another embodiment of the invention is directed to a therapeutic vaccine against B. anthracis comprising the EA1 antigen and/or monoclonal or polyclonal antibodies to the EA1 antigen (i.e. anti-EA 1-antibodies), and a pharmaceutically acceptable carrier. The entire protein (antibody or antigen), or an active portion thereof, can be used to vaccinate susceptible individuals to prevent or treat an infection. Antibodies provide passive immunity, most useful as treatment after exposure, and antigens provide active immunity for long term protection and prophylaxis. Preferably, antigens stimulate the immune system to create a cellular and/or antibody response in the individual vaccinated. Another embodiment of the invention is directed to a method for vaccinating against B. anthracis comprising administering the EA1 antigen or anti-EA1 antibody to a patient. The invention also includes therapeutic agents comprising antibodies to the EA1 protein and to methods for treating, preventing or controlling B. anthracis infection comprising administering an effective amount of antibodies to the EA1 antigen to a patient.
The following examples illustrate embodiments of the invention, but should not be view as limiting the scope of the invention.

Examples

Immunizations

Balb/c mice were immunized subcutaneously with B. anthracis spores prepared from the Sterne vaccine strain at three to four week intervals for up to five months. The first immunization was with 200 ug antigen in Freund's complete adjuvant. Subsequent boosts were with 100 ug antigen in Freund's incomplete adjuvant. Seven days prior to the fusion, mice were injected intravenously (iv) with 5 ug B. thuringiensis spores, of the Al Hakam and HD-571 strains (obtained from Los Alamos National Laboratories) combined into one antigen preparation. Seventy-two hours prior to the fusion, mice were immunized iv with 5 ug B. anthracis spores in PBS. Mouse sera was tested by direct ELISA after the third boost, and periodically after that to test antibody titers to B. anthracis spores.
Fusions
Hybridoma cells were developed to B. anthracis spores by fusion of nonsecreting myeloma cells (SP2/0) with antibody-producing B-lymphocytes from the spleens of mice immunized with B. anthracis spores, in the presence of polyethylene glycol (PEG), according to standard hybridoma procedures. Cells were combined in a ratio of 3:1 (spleen:myeloma), and fused with PEG. Fused cells were plated, and cultured in 96-well cell culture grade plates. Fused cells were then selected by addition of HAT media [Iscove's Modified Dulbecco's Media (IMDM) with HAT supplement containing hypoxanthine, aminopterin, and thymidine]. These HAT supplements select for the fused hybridoma cells, and eliminate unfused or self-fused myeloma cells. Once clones appeared in the wells (usually 7-10 days after fusion), the culture supernatants were screened by ELISA for antibodies to B. anthracis spores. Positive antibody producing cells were subcloned by serial dilution, and plated at a cell concentration of three cells per well, and then further at one cell per three wells in a 96-well culture plate. This was performed with ten percent ORIGIN® Hybridoma Cloning Factor (HCF) in IMDM. Between each cloning step, culture supernatants were screened by ELISA for antibody production. Finalized clones were screened for isotype, and cryopreserved in liquid nitrogen. Two fusions were performed resulting in the generation of numerous monoclonal antibodies to Bacillus anthracis (Table 1).
ELISA Screening
Cell supernatants were screened by direct ELISA. ELISA plates were coated with B. anthracis spore and vegetative preparation antigens as positive antigen, and bovine serum albumin (BSA) as negative antigen, diluted to an optimized concentration in PBS. Plates were incubated 18-24 hours at 4° C. Plates were washed four times with PBS. Cell supernatants were added to both positive and negative coated antigen wells, undiluted. Mouse sera from the immunized mice was added to plate at a dilution of 1:200, and serially diluted to an endpoint. This was included as a positive control. Plates were incubated at 37° C. for one hour. Plates were washed four times with PBS. Horseradish peroxidase (HRP) conjugated goat anti mouse IgG+M+A (KPL) was added to all wells, and incubated at 37° C. for one hour. Plates were washed four times with PBS. Substrate was added to plates and incubated at 37° C. for 30 minutes. Plates were read for optical density at 280 nm, and evaluated for positive results. Cells producing the highest optical density readings, i.e., above 1.000 OD, were subcloned. After each subcloning, cell supernatants were screened for positive antibody. Finalized clones were tested for isotype using monoclonal antibody-based mouse Ig isotyping kit (catalog #04017K; BD PharMingen). Three monoclonal antibodies (termed AX-EA1-G1, 8G4, and 9F5) were selected for their ability to uniquely detect B. anthracis and not cross-react with other closely related Bacillus species. Monoclonal antibody AX-EA1-G1 was deposited with the ATCC and accorded accession number PTA-2632, on Oct. 26, 2000. The selection of these monoclonal antibodies was based on their strong reactivity against B. anthracis antigens and their negative reactivity against the closely related strains of B. thuringiensis (ATCC 33680, HD571, Al Hakam, and commercial insecticide preparation from Dipel Dust), B. globigii and B. licheniformis (ATCC 25972) (Table 2, 3 and 4). In addition, these monoclonal antibodies were negative when tested against a selected number of other bacteria (Francisella tularensis and Yersinia pestis), purified proteins (ovalbumin and S. aureus enterotoxin B), and environmental components (red clay, gravel, and mulch) (Table 2, 3 and 4).
Specificity Testing
To test for cross-reactivity, an antigen capture ELISA was performed. Plates were coated with rabbit anti-anthrax IgG antibody as positive capture, and normal rabbit IgG as negative capture antibody. Plates were incubated overnight at 4° C. Plates were washed four times with PBS and then blocked with dry skim milk buffer. Plates were incubated for one hour at 37° C., and washed four times with PBS. Antigens were added to both positive and negative antibody coated wells at concentrations determined for cross-reactivity analysis. Plates were incubated for one hour at 37° C., and washed four times with PBS. Monoclonal antibodies (Mabs) were added to the plate at optimized concentrations, as detector antibodies. Plates were incubated for one hour at 37° C., and washed four times with PBS. Anti-species conjugate was added to the plate. Plates were incubated for one hour at 37° C., and washed four times with PBS. Substrate solution was added to the plate, and incubated for 30 minutes at 37° C. Plates were read at 280 nm for optical density readings.
Identification and Affinity Purification of B. anthracis Antigen An affinity column was made using the anthrax-specific monoclonal antibody AX-EA1-G1 complexed to the Immunopure Protein G IgG Orientation Kit (Pierce; Rockford, Ill.), according to manufacture's protocol. An anthrax spore antigen preparation was affinity purified over the column using the manufacturer's protocol.
SDS PAGE and Electroblotting
Affinity-purified anthrax antigens under went electrophoresis by SDS-PAGE on a 4-15% Tris-HCl polyacrylamide Ready Gel Precast Gel in a Mini-Protean 3 Electrophoresis Cell (Bio-Rad; Hercules, Calif.). Specifically, affinity-purified anthrax antigens (5.7 ug total), along with tubes containing molecular weight markers, were diluted in sample buffer (62.5 mM Tris-HCl pH 6.8, 2% SDS, 25% glycerol, 0.01% Bromophenol blue), boiled for 2.5 minutes, loaded onto the 4-15% gel and under went electrophoresis at 200V for 30 minutes.
The electroblotting procedure was performed according to the protocol posted on the Michigan State web site (http://gaea.bch.msu.edu/mssef/blotting.html) by the method of Matsudaira (J Biol Chem, 1987, 262:100035). Briefly, a 0.2 um PVDF membrane (Sequi-Blot PVDF Membrane for Protein Sequencing; Bio-Rad) was wet with methanol, soaked in CAPS/methanol buffer, electroblotted in a Mini Trans-Blot Electrophoresis Transfer Cell (Bio-Rad) at 50 V for one hour, according to manufacturer's instructions, in CAPS/methanol buffer.
The blotted PVDF membrane was stained with 0.2% Amido Black in 40% methanol for 40 seconds and destained in dH₂O. Two bands, of approximate molecular weight of 97 kD (“Band 1”) and 62 kD (“Band 2”), were visualized.
Protein Sequencing
Monoclonal antibody AX-EA1-G1 was used to affinity purify the specific B. anthracis antigen that the antibody was detecting. The affinity-purified antigen(s) was separated on by SDS-PAGE and electroblotted onto a PVDF membrane. Two bands were visualized after staining at approximate molecular weights of 97 kD (Band 1) and 62 kD (Band 2); the membrane was sent to the Biotechnology Center of Utah State University for protein sequencing. The amino acid sequence was determined to be:

Band 1:

	A G K Z F P Z V P A G H	(SEQ ID NO 2)

	Band 1:
	D Z K Z N A Q A Y V T D	(SEQ ID NO 3)
	(Z = uncertain amino acid)

Using both of these amino acid sequences, a tblastn protein search of the Unfinished Microbial Genomes TIGR database of B. anthracis sequences was performed. An exact match was observed with the definitive amino acid sequences for Contig 1819. A BLAST search of GenBank using the nucleotide sequence of contig 1819 resulted in complete homology to the eag gene that codes for the EA1 protein of the B. anthracis S-layer. The amino acid position corresponding to the sequence of Bands 1 and 2 are illustrated in FIG. 1. Since the AX-EA1-G1 monoclonal antibody bound to both bands, it can be concluded that the epitope to which AX-EA1-G1 binds is located somewhere within amino acids 181-833.
Competitive Inhibition Analysis
To determine whether the monoclonal antibodies produced to B. anthracis compete for the same epitope(s), a competitive inhibition assay was performed. ELISA plates were coated with rabbit anti-anthrax IgG as positive capture antibody, and normal rabbit IgG as negative capture antibody. Plates were incubated overnight at 4° C. Plates were washed four times with PBS and then blocked with dry skim milk buffer. Plates were incubated for one hour at 37° C., and washed four times with PBS. Antigens were added to both positive and negative antibody coated wells at concentrations determined for inhibition analysis. Plates were incubated for one hour at 37° C., and washed four times with PBS. Three separate monoclonal antibodies were used in the competition at the detector antibody step. One Mab, labeled with biotin, was held constant while the other Mabs were unlabeled and combined separately at different concentrations, with the biotin labeled Mab. Each combination was prepared in a micro-tube rack, and then added to the plate at the same time. Plates were incubated for one hour at 37° C., and washed four times with PBS. Conjugated streptavidin was added to the plates and incubated for one hour at 37° C. Plates were washed and substrate solution added. Plates were incubated for 30 minutes, and read for optical density at 280 nm.
Having determined that the monoclonal antibody AX-EA1-G1 reacts with the EA1 protein of B. anthracis, the other two monoclonal antibodies, 8G4 and 9F5, were tested against affinity-purified antigen and shown to also react with the EA1 antigen (Table 1). Therefore, all three monoclonal antibodies were shown to bind to the same EA1 protein. However, competitive inhibition analysis revealed that while 8G4 and 9F5 effectively compete for binding to the same epitope on the EA1 protein as each other, AX-EA1-G1 does not compete with the binding of 8G4 and 9F5 and therefore binds to a different epitope on the EA1 protein (FIG. 2).
Other embodiments and uses of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. All references cited herein, including all U.S. and foreign patents and patent applications and U.S. Provisional patent No. 60/200,505, are specifically and entirely hereby incorporated herein by reference. It is intended that the specification and examples be considered exemplary only, with the true scope and spirit of the invention indicated by the following claims.

TABLE 1

Relative Scoring of ELISA Data Based on 0-3 Scale*

Antibody	Form	Isotype	Sp1**	Sp3	SpG1	SpG3	V1	V + M

1-9F6 (AX-EA1-G1)	Purified	IgG1	P/M	3	3	3 (+)	2	3
7-8G4-1D7	Purified	IgG1	2	3	3 (+)	3	3 (+)	3
7-3C3-2C2	Purified	IgG1	P/M	3	2	1	2	3
7-1D4-1G7	Purified	IgG1	1	3	2	3	3	3
7-6B6-1C9	Purified	IgG1	0	1	2	1	3	3
7-1E10-1B5	Purified	IgG1	0	1	2	1	3	2
7-9F5-2B11	Purified	IgG1	1	3	3 (+)	3	3	3
7-9C2-1C11	Purified	IgG1	1	3	2	3	3	3
7-5E4-1C10	Purified	IgG1	1	3	2	1	2	3
7-8D3-1E6	Cell sup	IgG1	0	1	0	0	1	P/M
7-2B11-1B10	Cell sup	IgG1	1	3	2	2	3	3
7-7E10-1D8	Cell sup	IgG1	0	P/M	P/M	P/M	2	1
7-9E8-1B11	Cell sup	IgG1	2 (+)	3	3	3	3	3
7-10E8	Cell sup	IgG1	1	3	3 (+)	3	2	3
7-1G7-1A6	Cell sup	IgG1	1	3	3	1	2	3
7-8D7	Cell sup	IgG1	1	3	2	2	2	3

		B. thuringeneisis***
	Affinity	@100 ug/ml

Antibody	Form	Isotype	M	C1	C2	(EA1)	Al Hakam	HD571

1-9F6 (AX-EA1-G1)	Purified	IgG1	3	0	1	3	0	0
7-8G4-1D7	Purified	IgG1	3	0	2	3	0	0
7-3C3-2C2	Purified	IgG1	3	1	1	2	0	0
7-1D4-1G7	Purified	IgG1	3	1	2	2	0	0
7-6B6-1C9	Purified	IgG1	2	0	2	3	0	0
7-1E10-1B5	Purified	IgG1	2	0	2	3	0	0
7-9F5-2B11	Purified	IgG1	3	1	2	3	0	0
7-9C2-1C11	Purified	IgG1	3	1	2	2	0	0
7-5E4-1C10	Purified	IgG1	3	1	1	2	0	0
7-8D3-1E6	Cell sup	IgG1	P/M	0	1	P/M	0	0
7-2B11-1B10	Cell sup	IgG1	3	P/M	2	2	0	0
7-7E10-1D8	Cell sup	IgG1	P/M	0	1	1	0	0
7-9E8-1B11	Cell sup	IgG1	3	1	2	3	0	0
7-10E8	Cell sup	IgG1	3	1	2	3	0	0
7-1G7-1A6	Cell sup	IgG1	3	1	1	2	0	0
7-8D7	Cell sup	IgG1	3	1	2	3	0	0

B-Rabbit anti-anthrax (polyclonal)	3 (OD =	3 (OD =
	1.542)	2.188)

*0 = negative result; 1-3 = positive result with 3 being the highest titers

**Key to antigen preparations on following page.

***Near neighbor of B. anthracis

P/M = Plus/Minus

(+) = Highest Titer in group

Key to Antigen Preparations Evaluated in Table 1

Sp1	Standard washed spore prepared from plates (Prepare according to procedure from
	Lot 260400-01, with washes in PBS)
Sp3	fresh spore culture prepared from plates (Wash off spores with dH2O and test by
	ELISA fresh)
SpG1	Standard washed spore prepared from modified G (Prepare according to procedure
	from Lot 210400-01, with washes in PBS)
SpG3	Fresh spore culture prepared from modified G (Test straight from modified G media,
	once in spore state)
VI	Vegetative cells grown on TSA plates, washed off plates in PBS; 2x centrifuge,
	resuspend pellet in PBS, freeze
V + M	Vegetative cells in culture media and tested fresh by ELISA; freeze remainder
M	Supernatant without vegetative cells
C1	Control 1 - frozen prep lot 260400-01
C2	Control 2 - frozen prep lot 210400-01

Affinity (EA1)AX-EA1-G1 affinity-purified antigen corresponding to EA1 protein

Denotes Frozen samples

TABLE 2

Specificity Testing Performance for Anthrax Capture ELISA with
Capture Ab: Rabbit anti Anthrax/Detector Ab: AX-EA1-G1 Mab

Positive Controls:

	Positive Control
Antigen Conc

50 ug/ml	not tested	40 ug/ml	0 889	1.00E+05	1 586
25 ug/ml	not tested	20 ug/ml	0 809	5 00E+04	1.278
12.5 ug/ml	not tested	10 ug/ml	0.394	2.50E+04	0.666
6.25 ug/ml	2 810	5 ug/ml	0 214	1.25E+04	0 312
3.13 ug/ml	2 924	2.5 ug/ml	0 088	6 25E+03	0 177
1.56 ug/ml	2 982	Blank	0 000	3 13E+03	0 093

*Bacillus thuringensis:



40 ug/ml	0 000	0.026	0 000	0.013	0 000
20 ug/ml	0 011	0 000	0.007	0 057	0.005
10 ug/ml	0 018	0.005	0 072	0 008	0.014
5 ug/ml	0 000	0 015	0.005	0.000	0 017
2.5 ug/ml	0.000	0 000	0.004	0.000	0.000
Blank	0 000	0 000	0.082	0 000	0.065

Other Bacillus species:

				B. licheniformis
Antigen			Antigen

50 ug/ml	0 000	0 000	2N	0 001
25 ug/ml	0 000	0 003	4N	0.000
12.5 ug/ml	0 004	0 000	8N	0 001
6.25 ug/ml	0 000	0 005	16N	0.000
3.13 ug/ml	not tested	not tested	32N	0 002
1.56 ug/ml	not tested	not tested	Blank	0.000

Other Bacteria:



50 ug/ml	0 007	0.002
25 ug/ml	0.012	0 004
12.5 ug/ml	0 008	0 004
6.25 ug/ml	0 004	0 001
3.13 ug/ml	0.004	0 003
1.56 ug/ml	0 004	0 003

Other Proteins and Toxins:


Antigen Conc

50 ug/ml	0.004	0.000
25 ug/ml	0.002	0.000
12.5 ug/ml	0.006	0.000
6 25 ug/ml	0 001	0 001
3 13 ug/ml	0.002	0.002
1 56 ug/ml	0 002	0 000

Misc.

Antigen
Dilution	Red Clay	Grey

2N	0.000	0 002	0.002
4N	0 004	0 007	0.001
8N	0 003	0 004	0 002
16N	0 001	0 001	0 002
32N	0.004	0.002	0.001
64N	0 003	0 001	0 000

Nearest neighbor of B. anthracis*
**Prepared by adding 0 5 g to 3 ml ELISA buffer; vortex and let settle 15 min before addition to plate
Red highlighted optical density readings are positive results
indicates data missing or illegible when filed

TABLE 3

Specificity Testing Performance for Anthrax Capture ELISA
with Capture Ab: Rabbit anti Anthrax/Detector Ab: 8G4 Mab

Positive Controls:


Antigen Conc

50 ug/ml	2 763	2 803	2 645
25 ug/ml	2 781	2 705	2 658
12.5 ug/ml	2 786	2 686	2.519
6.25 ug/ml	2 729	2 663	2 561
3.13 ug/ml	2 718	2 655	2 570
1.56 ug/ml	not tested	not tested	2 767

*Bacillus thuringensis:



40 ug/ml	0 001	0 002	0 020	0 027	0 024
20 ug/ml	0 022	0 000	0 011	0 040	0 011
10 ug/ml	0 104	0.018	0.017	0.025	0.000
5 ug/ml	0.001	0 000	0.017	0.000	0.033
2.5 ug/ml	0 000	0 012	0.002	0 000	0.003
Blank	0 011	0 008	0 010	0 005	0 017

Other Bacillus species:



50 ug/ml	0.000	not tested	2N	0.001
25 ug/ml	0 000	not tested	4N	0.004
12.5 ug/ml	0 012	not tested	8N	0 001
6.25 ug/ml	0 000	not tested	16N	0 002
3.13 ug/ml	0 076	not tested	32N	0 004
1.56 ug/ml	0 041	not tested	Blank	0 002

Other Bacteria:

		Y. Pestis
Antigen Conc

50 ug/ml	0 000	0 000
25 ug/ml	0 000	0 000
12.5 ug/ml	0 000	0.000
6.25 ug/ml	0.000	0.000
3.13 ug/ml	0 000	0 000
1.56 ug/ml	0 013	0 000

Other Proteins and Toxins:


Antigen Conc

50 ug/ml	0.000	0 000
25 ug/ml	0.002	0.000
12.5 ug/ml	0.102	0 005
6.25 ug/ml	0.040	0 000
3.13 ug/ml	0.111	0.004
1.56 ug/ml	0.081	0 003

Misc.

Antigen
Dilution	Red Clay	Grey

2N	0 000	0 000	0 000
4N	0.000	0 038	0.013
8N	hot well	0 008	0.012
16N	0.019	0 000	0.028
32N	0 000	0.049	0.000
64N	0 000	0 000	0.002

Nearest neighbor of B anthracis*
**Prepared by adding 0.5 g to 3 ml ELISA buffer, vortex and let settle 15 mm before addition to plate
Red highlighted optical density readings are positive results
indicates data missing or illegible when filed

TABLE 4

Specificity Testing Performance for Anthrax Capture ELISA with
Capture Ab: Rabbit anti Anthrax/Detector Ab: 9F5 Mab

Positive Controls:



50 ug/ml	2.885	2.927	2.284
25 ug/ml	2.835	2.795	2.226
12.5 ug/ml	2.891	2.807	1.834
6.25 ug/ml	2.721	2.801	1.821
3.13 ug/ml	2.700	2.772	1.885
1.56 ug/ml	0.000	0.009	1.539

*Bacillus thuringensis:



50 ug/ml	0.116	0.003	0.001	100 ug/ml	0.073	0.049
25 ug/ml	0.086	0.000	0.000	20 ug/ml	0.029	0.029
12.5 ug/ml	0.049	0.002	0.001	4 ug/ml	0.004	0.007
6.25 ug/ml	0.064	0.000	0.000	Blank	0.000	0.001
3.13 ug/ml	0.033	0.000	0.000
1.56 ug/ml	0.045	0.000	0.001

Other Bacillus species:



50 ug/ml	0.000	not tested	2N	0.000
25 ug/ml	0.000	not tested	4N	0.000
12.5 ug/ml	0.000	not tested	8N	0.002
6.25 ug/ml	0.000	not tested	16N	0.003
3.13 ug/ml	0.014	not tested	32N	0.000
1.56 ug/ml	0.081	not tested	Blank	0.000

			Other
	Other Bacteria:		Proteins and Toxins:



50 ug/ml	0.000	0.000	50 ug/ml	0.029	0.000
25 ug/ml	0.000	0.042	25 ug/ml	0.000	0.000
12.5 ug/ml	0.048	0.002	12.5 ug/ml	0.043	0.000
6.25 ug/ml	0.000	0.000	6.25 ug/ml	0.000	0.009
3.13 ug/ml	0.032	0.000	3.13 ug/ml	0.030	0.013
1.56 ug/ml	0.000	0.000	1.56 ug/ml	0.008	0.000

Misc.



2N	0.047	0.104	0.011
4N	0.000	0.000	0.000
8N	hot well	0.000	0.009
16N	0.012	0.000	0.006
32N	0.026	0.000	0.001
64N	0.079	0.000	0.000

*Nearest neighbor of B anthracis
**Prepared by adding 0.5 g to 3 ml ELISA buffer: vortox and let settle 15 min before addition to plate
Red highlighted optical density readings are positive results
indicates data missing or illegible when filed

Claims

1. A monoclonal antibody which is specifically reactive against B. anthracis.

2. The antibody of claim 1 which is non-reactive against B. cereus or B. thuringiensis.

3. The antibody of claim 1 which is an IgA, IgD, IgE, IgG or IgM.

4. The antibody of claim 1 which is reactive against a surface protein of B. anthracis.

5. The antibody of claim 4 wherein the surface protein is an EA1 protein.

6. The antibody of claim 1 which binds to SEQ ID NO. 1.

7. The antibody of claim 1 which is specifically reactive against B. anthracis spores.

8. The antibody of claim 1 which is specifically reactive against B. anthracis vegetative cells.

9. A hybridoma that produces the antibody of claim 1.

10. The hybridoma of claim 9 which is derived from an animal selected from the group consisting of cattle, chickens, goats, guinea pigs, horses, mice, pigs, primates, rabbits, rats and sheep.

11. A hybridoma deposited with ATCC and accorded accession number PTA-2632.

12. Antibody isolated from the hybridoma of claim 11.

13. An isolated antibody, or reactive portion thereof, directed to the EA1 protein of B. anthracis.

14. The antibody or reactive portion thereof of claim 13 which is a murine antibody; a rabbit antibody; a rat antibody; a genetically engineered antibody; a recombinant antibody; a humanized antibody; a polyclonal antibody or an affinity-purified antibody.

15. The antibody or reactive portion thereof of claim 13 which is an Fab or Fv fragment.

16. A diagnostic kit comprising an antibody that is specifically reactive against spores or vegetative cells of B. anthracis, B. thuringiensis or B. cereus.

17. The diagnostic kit of claim 16 which incorporates a colloidal particle based lateral flow detection system.

18. The diagnostic kit of claim 16 which incorporates a detection system selected from the group consisting of a carbon based lateral flow system; a fluorescent based assay system, a chemiluminescent system, an up converting phosphors system, a refractive indexed based detection system, a magnetic bead or latex bead system, and a micro array system.

19. A diagnostic kit comprising an antibody that is specifically reactive against spores of B. anthracis and not B. thuringiensis, and incorporates a colloidal particle based lateral flow detection system.

20. A diagnostic kit comprising an antibody that is specifically reactive against spores of B. thuringiensis and not B. anthracis, and incorporates a colloidal particle based lateral flow detection system.

21. A method for producing a species-specific monoclonal antibody to one species of Bacillus comprising:

immunizing a host with a preparation of said one species of Bacillus;

boosting said host with another preparation of an antigenically similar, but not identical, species of Bacillus;

boosting said host with said preparation of said one species;

fusing antibody-producing cells from the host with immortalized cells; and

selecting a hybridoma that produces the species-specific monoclonal antibody to said one species of Bacillus.

22. The method of claim 21 wherein the one species of Bacillus is B. cereus, B. thuringiensis or B. anthracis.

23. The method of claim 21 wherein the other antigenically similar species of Bacillus is B. cereus, B. thuringiensis, B. anthracis or combinations thereof.

24. The method of claim 21 wherein the one species of Bacillus is B. anthracis and the other antigenically similar species of Bacillus is B. cereus or B. thuringiensis.

25. The method of claim 21 wherein the one species of Bacillus is B. thuringiensis and the other antigenically similar species of Bacillus is B. cereus or B. anthracis.

26. The method of claim 21 wherein the preparation of said one species comprises spores, vegetative cells or combinations thereof.

27. The method of claim 21 wherein the preparation of said other antigenically similar species comprises spores, vegetative cells or combinations thereof.

28. The method of claim 21 wherein the species-specific monoclonal antibody is selected from the group consisting of IgA, IgE, IgG, IgM and associated sub-types.

29. The method of claim 21 wherein the host is selected from the group consisting of mice, rats, horses, cattle, chickens, sheep, goats, pigs and primates.

30. The method of claim 21 wherein boosting with the antigenically similar species is performed about seven days prior to fusing.

31. The method of claim 21 wherein boosting with B. anthracis is performed about three days prior to fusing.

32. A species-specific monoclonal antibody to spores of B. anthracis made by the method of claim 21.

33. A diagnostic kit comprising the antibody of claim 32.

34. A hybridoma that expresses the antibody of claim 32.

35. An antibody which is specifically reactive against B. thuringiensis and non-reactive against B. cereus or B. anthracis.

36. An antibody which is specifically reactive against B. cereus and non-reactive against B. anthracis or B. thuringiensis.

37. An isolated or recombinant antigen, or antigenically active portions thereof, comprising an EA1 protein of the surface layer of B. anthracis.

38. A pharmaceutical composition comprising the antigen, or active portions hereof, of claim 37 and a pharmaceutically acceptable carrier.

39. A method of using the antigen, or active portions thereof, of claim 37 as the target for an immunological detection system for B. anthracis.

40. A vaccine against B. anthracis comprising a therapeutically effective amount of the antigen, or active portions thereof, of claim 37.

41. A method for vaccinating against B. anthracis comprising administering the therapeutically effective amount of the vaccine of claim 40 to a patient.

42. A therapeutic agent comprising antibodies to the EA1 protein.

43. A method for treating, preventing or controlling B. anthracis infection comprising administering an effective amount of the therapeutic agent of claim 42 to a patient.